SUNPHARMA.NS - Sun Pharmaceutical Industries Limited

NSE - NSE Real Time Price. Currency in INR
514.25
+8.95 (+1.77%)
At close: 3:29PM IST
Stock chart is not supported by your current browser
Previous Close505.30
Open505.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range505.00 - 515.50
52 Week Range432.70 - 656.95
Volume2,423,784
Avg. Volume5,749,775
Market Cap1.234T
Beta0.42
PE Ratio (TTM)58.90
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield3.50 (0.68%)
Ex-Dividend Date2017-09-18
1y Target EstN/A
  • Reuters5 days ago

    BRIEF-Sun Pharmaceutical Industries' Unit Raises Stake In Ranbaxy Malaysia

    April 18 (Reuters) - Sun Pharmaceutical Industries Ltd : * UNIT RAISED STAKE IN RANBAXY MALAYSIA VIA FURTHER PURCHASE OF 394,404 SHARES OF RANBAXY MALAYSIA * SAYS POST SHARE PURCHASE, CO'S TOTAL HOLDING ...

  • Sun Pharmaceutical Announces First U.S. Approval for Novel Drug
    Bloomberglast month

    Sun Pharmaceutical Announces First U.S. Approval for Novel Drug

    Sun Pharmaceutical Industries Ltd., India’s largest drug maker, has announced its first U.S. approval for an innovative medicine, marking a milestone in the company’s bid to diversify out of generic drugs ...

  • Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA): Time For A Financial Health Check
    Simply Wall St.last month

    Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA): Time For A Financial Health Check

    Investors pursuing a solid, dependable stock investment can often be led to Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA), a large-cap worth ₹1.24T. Doing business globally, large caps tend to have diversifiedRead More...

  • Sun Pharma quarterly profit plunges on weak U.S. sales
    Reuters2 months ago

    Sun Pharma quarterly profit plunges on weak U.S. sales

    Sun Pharma, along with other Indian pharmaceutical companies, has been battling increased competition in the generics market and greater pricing scrutiny in the United States. The drugmaker has also struggled as some of its products were banned from sale in the United States because the factories that made them did not meet U.S. quality standards. It was also hit by adjustments for U.S. tax reforms in the third quarter.

  • At INR557.45, Is Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) A Buy?
    Simply Wall St.2 months ago

    At INR557.45, Is Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) A Buy?

    Today we’re going to take a look at the well-established Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA). The company’s stock saw a double-digit share price rise of over 10% in the pastRead More...

  • Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA): Does -56.99% Earnings Drop In A Year Reflect The Long-Term Trend?
    Simply Wall St.4 months ago

    Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA): Does -56.99% Earnings Drop In A Year Reflect The Long-Term Trend?

    When Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) announced its most recent earnings (30 September 2017), I did two things: looked at its past earnings track record, then look at what isRead More...

  • Sensex, Nifty retreat from record highs
    Reuters4 months ago

    Sensex, Nifty retreat from record highs

    The Sensex and the Nifty fell on Wednesday, retreating from record highs hit earlier in the session, after business news channel ET Now said the government could borrow more than what it has currently budgeted for the remainder of the fiscal year ending March. The Sensex dropped 0.29 percent to close at 33,911.81 after earlier rising as much as 0.37 percent to a record high of 34,137.97.

  • Reuters5 months ago

    Morning News Call - India, November 15

    To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_11152017.pdf If you would like to receive this newsletter via email, please register ...

  • Sun Pharma posts profit dive on U.S. pricing pressure
    Reuters5 months ago

    Sun Pharma posts profit dive on U.S. pricing pressure

    REUTERS - India's largest drugmaker Sun Pharmaceutical Industries reported a 59 percent plunge in second-quarter profit on Tuesday, hurt by generics pricing pressure in the United States. Along with other ...

  • Sun Pharma Suffers as FDA Sanctions Exacerbate Generic Woes
    Bloomberg5 months ago

    Sun Pharma Suffers as FDA Sanctions Exacerbate Generic Woes

    Sun Pharmaceutical Industries Ltd.’s profit more than halved as it lost exclusivity on a key U.S. product, increasing pressure on the company to resolve issues at a plant that has hampered new product ...

  • Reuters6 months ago

    BRIEF-Sun Pharmaceutical Industries says unit raises shareholding in Ranbaxy Malaysia Sdn Bhd

    Oct 12 (Reuters) - Sun Pharmaceutical Industries Ltd * Unit agreed to increase shareholding in Ranbaxy Malaysia Sdn Bhd via purchase of 666,985 shares of Ranbaxy Malaysia Source text - http://bit.ly/2g5YoTO ...

  • Reuters6 months ago

    Sensex rises ahead of key corporate results

    REUTERS - Indian shares extended gains on Thursday with the NSE index clocking its biggest percentage gain since May 25 as excitement builds up ahead of some key quarterly results including that from Tata ...

  • Cheap Drugs Pay for Aurobindo as U.S. FDA Approvals Surge
    Bloomberg7 months ago

    Cheap Drugs Pay for Aurobindo as U.S. FDA Approvals Surge

    While India’s largest pharmaceutical companies have seen drug approvals in the U.S. slow overall, their research and development spending has been on a run. Not so for Aurobindo Pharma Ltd.Quarter after ...

  • Reuters8 months ago

    Morning News Call - India, August 14

    To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_08142017.pdf If you would like to receive this newsletter via email, please register ...

  • Billionaire Shanghvi's Sun Pharma Surprises With Loss
    Bloomberg8 months ago

    Billionaire Shanghvi's Sun Pharma Surprises With Loss

    The billionaire founder of Sun Pharmaceutical Industries Ltd. pledged that the drugmaker would do better after reporting its first loss in at least 12 years amid regulatory headaches and a weakening market ...

  • Reuters9 months ago

    No more freebies? India plans crackdown on marketing by drugmakers

    India, one of the world's largest markets for pharmaceuticals is drawing up its first set of marketing rules for drugmakers, restricting gifts and trips offered to doctors and pharmacists to 1,000 rupees ($15), according to a draft proposal seen by Reuters. Such rules are common overseas, but are not set in stone in India, where campaigners have long demanded a crackdown on unethical selling practices that include gifts ranging from electrical appliances to foreign trips to woo physicians and pharmacists into prescribing and stocking specific medicines. The country has voluntary marketing guidelines for drugmakers, but critics say they are ineffective.

  • Sun Pharma Warns 'New Normal' Will Push Down Its Sales Next Year
    Bloomberg11 months ago

    Sun Pharma Warns 'New Normal' Will Push Down Its Sales Next Year

    Sun Pharmaceutical Industries Ltd., India’s largest drugmaker, warned investors that sales could decline in the coming year amid downward pressure on generic-drug prices in the U.S. and regulatory issues ...

  • Reuters11 months ago

    India's drugmakers need more time to meet intl standards-industry group

    India's big drugmakers will need at least five more years to improve their manufacturing standards and data reliability to a level demanded by international regulators, said a senior industry official. The lengthy timeline is a concern not only in India but around the world, as India's pharmaceutical firms supply a third of the drugs sold in the United States and a large percentage in other countries.